Get the Stockscreener App
1.17
5.88%
0.065
After Hours:
1.17
Rallybio Corp stock is traded at $1.17, with a volume of 33,900.
It is up +5.88% in the last 24 hours and up +1.74% over the past month.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$1.105
Open:
$1.15
24h Volume:
33,900
Relative Volume:
0.24
Market Cap:
$46.47M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.5995
EPS:
-1.9516
Net Cash Flow:
$-60.27M
1W Performance:
+6.36%
1M Performance:
+1.74%
6M Performance:
-36.76%
1Y Performance:
-65.28%
1-Day Range:
$1.11
$1.17
1-Week Range:
$1.09
$1.17
52-Week Range:
$1.08
$4.60
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - StockTitan
Rallybio reveals higher FNAIT risk across populations - Investing.com
Rallybio reveals higher FNAIT risk across populations - Investing.com India
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - StockTitan
Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Rallybio announces board member resignation - Investing.com
Rallybio announces board member resignation - Investing.com India
Rallybio announces board member resignation By Investing.com - Investing.com UK
Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee - TipRanks
Rallybio Corporation Announces Resignation of Kush Parmar as Member of Board and Chair of Nominating and Corporate Governance Committee, Effective October 31, 2024 - Marketscreener.com
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - StockTitan
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire
Rallybio - FiercePharma
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - StockTitan
Rallybio stock plunges to 52-week low, hits $1.09 - Investing.com
Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World
Rallybio reiterated at Buy at H.C. Wainwright on FNAIT drug data - Investing.com
Rallybio advances RLYB212 to phase 2 for FNAIT prevention - Investing.com India
Rallybio advances RLYB212 to phase 2 for FNAIT prevention - Investing.com
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis - Business Wire
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully - Simply Wall St
Rallybio to Present at Upcoming Investor Conferences - Elk Valley Times
Rallybio to Present at Upcoming Investor Conferences - Business Wire
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com Australia
HC Wainwright Comments on Rallybio Co.’s Q3 2024 Earnings (NASDAQ:RLYB) - Defense World
Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com
Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com UK
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Australia
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com Australia
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com India
Rallybio (NASDAQ:RLYB) PT Lowered to $6.00 - Defense World
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com UK
Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth? - Yahoo Finance
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates - StockTitan
Rallybio stock plunges to 52-week low at $1.12 amid market challenges - Investing.com
31,294 Shares in Rallybio Co. (NASDAQ:RLYB) Bought by Acadian Asset Management LLC - Defense World
Brokerages Set Rallybio Co. (NASDAQ:RLYB) Target Price at $12.20 - MarketBeat
Rallybio co-founder joins another CT bioscience company board - Hartford Business Journal
Rallybio Co. (NASDAQ:RLYB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors - StockTitan
Rallybio Co. (NASDAQ:RLYB) Sees Large Drop in Short Interest - MarketBeat
Rallybio co-founder to step down as executive chairman, leave full-time role - Hartford Business Journal
Rallybio Corp announces executive transition plan - Investing.com
Rallybio Executive Chairman Announces Plans to Step Down - TipRanks
Short Interest in Rallybio Co. (NASDAQ:RLYB) Drops By 16.9% - MarketBeat
Rallybio Co. (NASDAQ:RLYB) Short Interest Down 16.9% in June - Defense World
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):